Ontario Genomics Institute invests in stem cell technology at Tissue Regenerative Therapeutics

November 12th, 2012
The Ontario Genomics Institute (OGI), through its Pre-Commercialization Business Development Fund (PBDF), has invested in Toronto-based Tissue Regenerative Therapeutics (TRT), a company that aims to use umbilical mesenchymal stem cells (MSCs) to treat a variety of serious medical conditions, such as arthritis, diabetes and Crohn's disease, to name a few. TRT will use this investment to conduct studies required to apply for approval to initiate human clinical trials.

MSCs are cells that can differentiate into musculoco-skeletal tissues such as bone, cartilage and muscle. Their ability to generate replacement tissues and affect cellular processes such as inflammation makes them an exciting potential therapy for a variety of conditions. Unlike other cells, MSCs can be used without the need for tissue matching and can be accumulated in large numbers. TRT has developed new methods to extract MSCs from umbilical cords, eliminating many of the challenges related to MSC harvesting from other tissue sources.

"Stem cell research is a promising area of biomedical research and it could have significant impact for people suffering from many conditions," said Mark Poznansky, President and CEO, OGI. "TRT is an excellent example of an Ontario company developing innovative therapies and translating research into potential clinical applications."

TRT is aiming to launch clinical trials to test these cells within the next two years. The PBDF funding from OGI will fund proteomic and transcriptomic analyses to further understand TRT's stem cells. These studies will provide valuable information needed for regulatory approval to conduct human clinical trials and further differentiate their product from those of competitors.

"We believe that these stem cells represent a unique and potent means of treating multiple debilitating diseases," said John Davies, CEO of TRT. "The OGI funding will enable us to demonstrate the utility of our cells for clinical applications using cutting edge technologies."

OGI's PBDF program invests in opportunities—based in genomics, proteomics or associated technologies—that fall in the proof-of-principle (validation) phase of research and that have the short-term potential to secure a significant next step towards the marketplace. Previous recipients have included Ontario universities, research institutes and companies.

Provided by Ontario Genomics Institute

This Phys.org Science News Wire page contains a press release issued by an organization mentioned above and is provided to you “as is” with little or no review from Phys.Org staff.

More news stories

Finding faster-than-light particles by weighing them

In a new paper accepted by the journal Astroparticle Physics, Robert Ehrlich, a recently retired physicist from George Mason University, claims that the neutrino is very likely a tachyon or faster-than-light par ...

Taxi app Uber defies ban in Spain

Smartphone car-ride service Uber vowed Friday to keep operating in Spain despite a ban following a lawsuit by taxi drivers and said it would fight the case in court.

Pregnant woman taken off life support in Ireland

A brain-dead pregnant woman was taken off life support Friday after a court ruled that her 18-week-old fetus was doomed to die—a case that exposed fear and confusion among doctors over how to apply Ireland's ...

Methane is leaking from permafrost offshore Siberia

Yamal Peninsula in Siberia has recently become world famous. Spectacular sinkholes, appeared as out of nowhere in the permafrost of the area, sparking the speculations of significant release of greenhouse ...